View all results
No results
News
Events
The industry
arrow_drop_down
Industry overview
Industrial biotech
Swiss Biotech Report
Success Stories
Company directory
Jobs
Networking platforms
Newsletter
Association
arrow_drop_down
Mission and services
Members
Academy
Partners
Team
Media
Add listing
Log in
or
Register
0
Add listing
EPEC/EAEC
Product
prev
next
Leave a review
Claim listing
Bookmark
Share
Report
prev
next
Indicaton
Prevention of EPEC/EAEC Infection
Therapeutic indications
Infectious disease
Company
Humabs BioMed AG
You may also be interested in
Debio 4028
Infectious diseases Debio 4028 program leverages the immunomodulatory, pro-apoptotic and virus-reactivating properties of a new generation of potent, orally available Inhibitor of Apoptosis Proteins (IAP) antagonists to cure various chronic infectious diseases. These new molecules are expected to allow the discontinuation of any antiviral treatment and eliminate the risk of clinical relapse, transmission of the infection and long-term complications.
Discovery
Debio 1454/M
GI disorders
Discovery
MV-003 Dysbiosis
Dysbiosis ApyraMed promotes microbiome recovery and selection of beneficial bacteria after antibiotic treatment. This results in powerful control of antibiotic-induced enteric infections and metabolic alterations.
Discovery
Cart
×
View all results
No results
Facebook
Twitter
WhatsApp
Telegram
Pinterest
LinkedIn
Tumblr
VKontakte
Mail
Copy link
This site uses cookies:
Find out more.
Accept
